Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

Launched by NATIONAL INSTITUTE OF BLOOD AND MARROW TRANSPLANT (NIBMT), PAKISTAN · Jun 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called thalidomide on patients with a genetic disorder known as beta thalassemia, which causes serious anemia and often requires regular blood transfusions. The trial aims to understand how different doses of thalidomide can help manage this condition while also looking at the safety of the drug. It will involve 54 patients aged 8 to 35 years at NIBD hospital over two years. Researchers will collect information about patients’ blood levels and overall health to see how well the treatment is working and if there are any side effects.

To participate in this study, patients must have been diagnosed with beta thalassemia major or intermediate and need to be willing to give their consent. However, certain individuals, such as those with liver problems, married individuals, lactating mothers, or those with a history of blood clots or seizures, won't be eligible to join. Participants can expect regular check-ups and assessments throughout the trial as researchers gather important data that could help improve treatment options for beta thalassemia in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Know case of beta thalassemia major/ intermediate ( transfusion dependent)
• • willing to give informed consent
• Exclusion Criteria:
• • Patients with comorbidities such as liver dysfunction
• • Married patients
• • Lactating mother
• • H/O thrombosis and fits